|
Post by op2778 on Jul 15, 2016 19:06:36 GMT -5
Lol. Do you think a CEO not going to conferences calls, or saying: we are not going to diluite and just after he finished the ER do exactly the opposite is a guy with "balls"?
We can argue whatsoever you want, but this is not a good CEO. In fact, just think about it, last Mr AL effort was to hire DeSisto. Now, What happened to DeSisto we all know (the question is: poor mgmt study about Desisto legal situation?? Why??) and with none to get the CEO place they decided to put Matt as CEO.
until now (share price proves it) Matt doesn't delivered to shareholders, instead, looks like he is in doing all possible to help the other side to cover....
Do you need more facts? Transparency? Do i need to remember VDex? Who are they? Crickets..... RLS? Allen? I dont know, just hope some Mr AL friend trying to keep MNKD a float.
Retinas detachment? Well, that can happen, but, please, dont defend Matt.....
he can proves me wrong, i hope he will, but until now, just smokes and mirrors.
nice weekend Op
|
|
|
Post by nylefty on Jul 15, 2016 19:50:24 GMT -5
Order received and rejected. I'd much rather have Mike speak than Matt for the simple reason that Mike is a much better public speaker. Matt never "promised" that there would be no dilution. And Vdex and RLS will decide when they want to reveal themselves. It's not up to Matt or anyone else at MannKind.
|
|
|
Post by mnholdem on Jul 15, 2016 19:50:37 GMT -5
Thank you for sharing your ideas, mannmade . I would add this thought to the conversation, because it was the hot topic during the Sanofi launch and, in my humble opinion, the events of the past year have driven home just how important it is. Health care professionals and patients alike have simply not been made aware of what makes Afrezza stand apart from other prandial insulin. If MannKind's new advertising agency lives up to its billing as an agency that specializes in marketing disruptive medicines, then we are in for a marketing campaign unlike anything we have seen. From materials for the HCP and clinics to a digital D-T-C blitz and eventually aired advertisements, a very important key to success is to build brand awareness on a large scale. Non-inferior does NOT mean not different. Afrezza is a one of a kind type of insulin that deserves is own classification, in my opinion. However, until the FDA decides that Afrezza merits a label change, then it's up to Marketing to show the world what makes Afrezza unique and desirable. Eye-opening educational material, a totally revamped website for Afrezza and a digital marketing blitz by the PrecisionEffect Agency may play an enormous role, not only in building brand awareness, but building it quickly. Take a look at impact on EXAS sales AND share price after the PrecisionEffect campaign began in the U.S. I think your message to be patient is great advice. That said, I have this gut feeling that once we finally see a BIG marketing campaign - which has NOT happened yet despite what some pundits claim - some folks are going to get really excited...and become a bit impatient. Mannmade, matt and others on this board are spot on for reminding us that there will be a ramp-up period between educating and robust script numbers. How long? I think that may depend largely on how effectively Afrezza is marketed. Build awareness and you will create demand. Good fortune to all.
|
|
|
Post by peppy on Jul 15, 2016 20:18:39 GMT -5
op, understand... I am not suggesting anything to expect or wait for at this point except script count (hopefully upward.) A R/S may be in the works but am not sure what it accomplishes if the underlying issues do not change. Will still be tough to get financing at this point. A 1,000 scripts may be high but they already have 224. So only need 776. That's roughly 100 scripts per rep in 3 months. Is it doable, I do not know but think it should be. If eacb rep sees 2 docs per day at 60 reps that's 600 docs per week and 2,400 docs per month. So theoretically it would only take 30% of docs called on in the first month to write 1 script each per week. Seems doable but who really knows until we know...? 627 total prescriptions was reached oct 23, 2015. The stock price $3.30. Sanofi's afrezza kickoff was june there were roughly 450 total prescriptions at that point. scripts going from 224 to 1000 in three months would be very encouraging. Huge for us.
|
|
|
Post by op2778 on Jul 15, 2016 21:17:54 GMT -5
We are agree about Mike speaking.
That's the only good thing Matt has done until now. i know you from ST. we are on the same page. Not agree about RLS and VDex comment. Basically you are saying Matt is like a puppet and that's not his role (specially when he gets a salary of more than 1mm+free options).
that said, Let's see What will happen with scripts.
Hope is the last resource we have...
Op
|
|
|
Post by mnholdem on Jul 15, 2016 22:34:16 GMT -5
Op, IMO, Pfeffer is acting as a placeholder until the new CEO arrives. That's why he has not hired a CFO replacement. The BoD will hire DeSisto this fall when his non-complete clause expires and Pfeffer will be retaining his CFO job. As far as you ridiculing Matt's not disclosing information when he's bound by one or more non-disclosure agreements, that seems to me to be like hitting a man who is handcuffed. If you honestly believe that hope is our only resource, you must not be very good at research.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 15, 2016 22:49:30 GMT -5
Op, IMO, Pfeffer is acting as a placeholder until the new CEO arrives. That's why he has not hired a CFO replacement. The BoD will hire DeSisto this fall when his non-complete clause expires and Pfeffer will be retaining his CFO job. As far as you ridiculing Matt's not disclosing information when he's bound by one or more non-disclosure agreements, that seems to me to be like hitting a man who is handcuffed. If you honestly believe that hope is our only resource, you must not be very good at research. I am not sure that will happen. Why would Pfeffer step down? given the heavy lifting now is being done by Mike. Didnt Matt get a ton of options recently for signing up as a CEO. Then again , can the company afford to hire another ceo with options and salary?
|
|
|
Post by mannmade on Jul 15, 2016 23:04:38 GMT -5
Let's not forget who found and hired Mike.
|
|
|
Post by gamblerjag on Jul 15, 2016 23:08:41 GMT -5
We know SNY put a feeble attempt in promoting Afrezza through a few magazines for a short time. Couldn't MNKD place an article in some diabetes magazines that go to Dr's offices that state that Afrezza is here to stay under MNKD; and a new plan in place with new supply amount. . I don't know how expensive that would be but it would reach a lot of physicians that SNY was telling lies about Afrezza.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 15, 2016 23:26:22 GMT -5
We know SNY put a feeble attempt in promoting Afrezza through a few magazines for a short time. Couldn't MNKD place an article in some diabetes magazines that go to Dr's offices that state that Afrezza is here to stay under MNKD; and a new plan in place with new supply amount. . I don't know how expensive that would be but it would reach a lot of physicians that SNY was telling lies about Afrezza. isnt that what the 60 reps visiting docs doing with the list of docs who have prescribed Afrezza as a priority?
|
|
|
Post by mnholdem on Jul 16, 2016 0:16:45 GMT -5
Op, IMO, Pfeffer is acting as a placeholder until the new CEO arrives. That's why he has not hired a CFO replacement. The BoD will hire DeSisto this fall when his non-complete clause expires and Pfeffer will be retaining his CFO job. [clipped] I am not sure that will happen. Why would Pfeffer step down? given the heavy lifting now is being done by Mike. Didnt Matt get a ton of options recently for signing up as a CEO. Then again , can the company afford to hire another ceo with options and salary? I hope you don't think I have any ill will against Matt. That is one terrific guy that has my utmost respect. But the answer to your question of why I think Matt would step down is that it's my belief that Matt agreed to do this when he took the job. Mann and the BoD wanted DeSisto (a great choice, by the way) and DeSisto agreed to become the new CEO. After Insulet chose not to waive the non-compete clause that binds DeSisto, I think everyone thought it best to have Matt fill the spot for nine months rather than to hire an interim CEO. Matt has been handsomely rewarded for doing this, IMO, and has done a good job and made some very good hires, although I think he may have had some advisor(s) counsel him in that regard. I like Matt Pfeffer. I also really like Hakan Edstrom, as my past posts will attest, but neither one of these gentlemen really has the experience that is needed for MannKind, IMO. This company is about way much more than Afrezza. If Afrezza is a golden egg, then remember that Technosphere is the goose. MannKind needs a CEO that has the experience to successfully navigate the pharmaceuticals industry and attract partnerships for a myriad of potential blockbuster drug candidates. Castagna is a great hire, and I think he'll do well marketing Afrezza, but MannKind must also secure partners to develop other drugs and must have the type of leader who has both the vision and the experience to successfully develop a disruptive drug delivery system that has the potential to radically improve medical treatment for millions.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 16, 2016 0:21:10 GMT -5
I am not sure that will happen. Why would Pfeffer step down? given the heavy lifting now is being done by Mike. Didnt Matt get a ton of options recently for signing up as a CEO. Then again , can the company afford to hire another ceo with options and salary? I hope you don't think I have any ill will against Matt. That is one terrific guy that has my utmost respect. But the answer to your question of why I think Matt would step down is that it's my belief that Matt agreed to do this when he took the job. Mann and the BoD wanted DeSisto (a great choice, by the way) and DeSisto agreed to become the new CEO. After Insulet chose not to waive the non-compete clause that binds DeSisto, I think everyone thought it best to have Matt fill the spot for nine months rather than to hire an interim CEO. Matt has been handsomely rewarded for doing this, IMO, and has done a good job and made some very good hires, although I think he may have had some advisor(s) counsel him in that regard. I like Matt Pfeffer. I also really like Hakan Edstrom, as my past posts will attest, but neither one of these gentlemen really has the experience that is needed for MannKind, IMO. This company is about way much more than Afrezza. If Afrezza is a golden egg, then remember that Technosphere is the goose. MannKind needs a CEO that has the experience to successfully navigate the pharmaceuticals industry and attract partnerships for a myriad of potential blockbuster drug candidates. Castagna is a great hire, and I think he'll do well marketing Afrezza, but MannKind must also secure partners to develop other drugs and must have the type of leader who has both the vision and the experience to successfully develop a disruptive drug delivery system that has the potential to radical improve medical treatment for millions. agreed . we will wait for Sep 17,2016
|
|
|
Post by surplusvalue on Jul 16, 2016 0:42:54 GMT -5
The shorts are not going anywhere since there appears to be no large catalyst on the horizon. Expect them to disappear slowly as the scripts rise slowly and in the meantime shorts will continue to try to batter the stock and drive the PPS down. Big pharma sees MNKD as a substantial threat and will do everything to crush it. This problem is not going to go away. I have seen this happen to other innovative products stepping on big pharma territory even to the point where politicians, who have aligned interests with particular pharma companies, step into the fray. Zohydro springs to mind.
MNKD 2.0 has a focused and restricted target (endos) but without greater public awareness of the product by diabetics giving the endos a push (demand side) to seriously consider using Afrezza instead of the status quo I don't expect any dramatic change in scripts will be that quick. Rather it will be slow. Understandibly MNKD, besides any other sound good reasons, have this focused sales approach precisely because of limited finances, the same limit that fences in any expensive partial DTC campaign now or a fuller one even later.
Besides DTC which apparently is planned for later by Precision, MKND needs a CEO who can be aggressively publicly visible to promote the existence of Afrezza now. Despite his merits, I don't see the present CEO rising to the occasion given his training and background. The main problem is the almost total lack of awareness of Afrezza. In my summary of the Cantor presentation that some of you reproduced here, one important and very disturbing problem that speaks to the awareness issue was that at ADA even the doctors that knew about Afrezza thought it was going off the market and that MNKD was done (thanks to Sanofi).
MNKD's transition from a development/production company to one that can market its products is a not an overnight transformation. Mike seems to know exactly what he is doing and thus MNKD finally has someone to commercialize the product. However, Mike and the team he has assembled cant be expected to pull all this off by themselves. The kind of CEO needed here to complement this 2.0 push is one with aggressive leadership skills active and visible publicly front and centre promoting the product and general awareness even before Precision steps in.
The main criticism I have stated before is that MNKD management has an uncanny ability to display no foresight. They did nothing in the way of preparation in case the Sanofi deal went south in execution; didnt protect themselves at all nor did they raise funds when they were in a much better position top do so for that rainy day. Water under the bridge, But no time like the present to have the foresight to see that public awareness needs to be dealt with alongside the targeted endo focus. Time pressure and limited funds should be forcing the awareness issue to centre stage.
|
|
|
Post by trondisc on Jul 16, 2016 1:07:14 GMT -5
Very realistic, mannmade; but you know me, I look at current affairs and say, "Is this the last hurrah for the longs." This whole thing has become so complex, so problematic; remember when it was this easy, "Afrezza will sell itself." Obviously, it never was that easy or even close to it. What most of us did not realize, and I include myself at the top of that list, is that we needed a Mike Castagna-type guy on board at the time we got approved. Hopefully, we snagged him in time. Babaoriley I'm in the same camp of "Is this the last hurrah for the longs." I'm 21 days away from my 1-year bagholder anniversary of the first time I purchased stock (along with several averaging down price points) in this company thinking they could make a difference changing modern medicine ala Technosphere. I feel like I'm waiting for the inevitable other shoe to drop in December when MannKind sells the company completely or goes BK. I'm so upset being a stuckholder with this company while management squanders a golden opportunity to take Technosphere to the next level with wireless monitoring. Imagine if MannKind management got off their ass and partnered with Dexcom/Verily?
|
|
|
Post by surplusvalue on Jul 16, 2016 1:21:31 GMT -5
..."Imagine if MannKind management got off their ass and partnered with Dexcom/Verily?" trondisc
Agreed. This is the other incredulous failure from management. Matt P. numerous times clearly stated that one primary thing that they learned from the Sanofi fiasco was that pairing Afrezza with CGM's was the key to its continued performance and success. If MNKD has acknowledged this themselves then why are they waiting for this collaboration to appear instead of actively promoting the collaboration themselves. It's like a MNKD syndrome... say something important but do nothing about it.
|
|